Molecular Neurodegeneration

Article	Citations
In Memoriam of John T. Trojanowski, MD, PhD 1946-2022	309
Mis-localization of endogenous TDP-43 leads to ALS-like early-stage metabolic dysfunction and progressive motor deficits	199
TREM2 dependent and independent functions of microglia in Alzheimer’s disease	194
Tau interactome and RNA binding proteins in neurodegenerative diseases	178
Regulation of the hippocampal translatome by Apoer2-ICD release	176
Guidelines for bioinformatics of single-cell sequencing data analysis in Alzheimer’s disease: review, recommendation, implementation and application	175
Emerging targets of α-synuclein spreading in α-synucleinopathies: a review of mechanistic pathways and interventions	172
Genome-wide histone acetylation analysis reveals altered transcriptional regulation in the Parkinson’s disease brain	157
Circadian clocks, cognition, and Alzheimer’s disease: synaptic mechanisms, signaling effectors, and chronotherapeutics	147
A genome-wide search for pleiotropy in more than 100,000 harmonized longitudinal cognitive domain scores	145
Neuroprotection by WldS depends on retinal ganglion cell type and age in glaucoma	143
Multimarker synaptic protein cerebrospinal fluid panels reflect TDP-43 pathology and cognitive performance in a pathological cohort of frontotemporal lobar degeneration	142
Inhibition of soluble epoxide hydrolase confers neuroprotection and restores microglial homeostasis in a tauopathy mouse model	139
Astrocytic autophagy plasticity modulates Aβ clearance and cognitive function in Alzheimer’s disease	133
Border-associated macrophages promote cerebral amyloid angiopathy and cognitive impairment through vascular oxidative stress	131
The Parkinson’s disease risk gene cathepsin B promotes fibrillar alpha-synuclein clearance, lysosomal function and glucocerebrosidase activity in dopaminergic neurons	131
Correction: Blood-brain barrier-associated pericytes internalize and clear aggregated amyloid-β42 by LRP1-dependent apolipoprotein E isoform-specific mechanism	130
HDGFL2 cryptic proteins report presence of TDP-43 pathology in neurodegenerative diseases	117
Unravelling cell type-specific responses to Parkinson’s Disease at single cell resolution	109
Multi-region brain transcriptomic analysis of amyotrophic lateral sclerosis reveals widespread RNA alterations and substantial cerebellum involvement	108
Sex dependent glial-specific changes in the chromatin accessibility landscape in late-onset Alzheimer’s disease brains	105
Single-cell peripheral immunoprofiling of Lewy body and Parkinson’s disease in a multi-site cohort	105
Human VCP mutant ALS/FTD microglia display immune and lysosomal phenotypes independently of GPNMB	103
The role of peripheral inflammatory insults in Alzheimer’s disease: a review and research roadmap	95
The role of NURR1 in metabolic abnormalities of Parkinson’s disease	88

Combination therapy using GDNF and cell transplant in Parkinson’s disease	86
Correction: Sodium oligomannate alters gut microbiota, reduces cerebral amyloidosis and reactive microglia in a sex-specific manner	86
BAX activation in mouse retinal ganglion cells occurs in two temporally and mechanistically distinct steps	83
APOE targeting strategy in Alzheimer’s disease: lessons learned from protective variants	82
Repetitive transcranial magnetic stimulation alleviates motor impairment in Parkinson’s disease: association with peripheral inflammatory regulatory T-cells and SYT6	80
α-Synuclein pathology disrupts mitochondrial function in dopaminergic and cholinergic neurons at-risk in Parkinson’s disease	80
Alzheimer risk gene product Pyk2 suppresses tau phosphorylation and phenotypic effects of tauopathy	79
Selective reduction of astrocyte apoE3 and apoE4 strongly reduces Aβ accumulation and plaque-related pathology in a mouse model of amyloidosis	78
Finding memo: versatile interactions of the VPS10p-Domain receptors in Alzheimer’s disease	77
Correction: The major TMEM106B dementia risk allele affects TMEM106B protein levels, fibril formation, and myelin lipid homeostasis in the ageing human hippocampus	66
A perspective on Alzheimer’s disease: exploring the potential of terminal/paradoxical lucidity and psychedelics	66
TMEM106B aggregation in neurodegenerative diseases: linking genetics to function	64
ASO-mediated knock-down of GPNMB in mutant-GRN and in Grn-deficient peripheral myeloid cells disrupts lysosomal function and immune responses	63
Deficits in mitochondrial TCA cycle and OXPHOS precede rod photoreceptor degeneration during chronic HIF activation	63
The transcription factor combination MEF2 and KLF7 promotes axonal sprouting in the injured spinal cord with functional improvement and regeneration-associated gene expression	61
Correction: HDGFL2 cryptic proteins report presence of TDP-43 pathology in neurodegenerative diseases	60
Using mass spectrometry to validate mouse models of tauopathy	60
Contribution of amyloid deposition from oligodendrocytes in a mouse model of Alzheimer’s disease	60
Common features of neurodegenerative disease: exploring the brain-eye connection and beyond (part 2): the 2021 pre-symposium of the 15th international conference on Alzheimer’s and Parkinson’s disease	59
Dementia with lewy bodies patients with high tau levels display unique proteome profiles	59
Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease	58
Oligomerization of Lrrk controls actin severing and α-synuclein neurotoxicity in vivo	57
Blood-based biomarkers of inflammation in amyotrophic lateral sclerosis	54
Neuropathology of incidental Lewy body & prodromal Parkinson’s disease	53
The endotoxin hypothesis of Alzheimer’s disease	53
RETRACTED ARTICLE: Aging exacerbates the brain inflammatory micro-environment contributing to α-synuclein pathology and functional deficits in a mouse model of DLB/PD	52
The role of n-3-derived specialised pro-resolving mediators (SPMs) in microglial mitochondrial respiration and inflammation resolution in Alzheimer’s disease	49
Brain mechanisms underlying neuropsychiatric symptoms in Alzheimer’s disease: a systematic review of symptom-general and –specific lesion patterns	49
Modulating innate immune activation states impacts the efficacy of specific Aβ immunotherapy	49
Novel App knock-in mouse model shows key features of amyloid pathology and reveals profound metabolic dysregulation of microglia	49
Microglial TYROBP/DAP12 in Alzheimer’s disease: Transduction of physiological and pathological signals across TREM2	48
Correction: Network proteomics of the Lewy body dementia brain reveals presynaptic signatures distinct from Alzheimer’s disease	48
Correction: Predominant expression of Alzheimer’s disease-associated BIN1 in mature oligodendrocytes and localization to white matter tracts	47
Parkinson mice show functional and molecular changes in the gut long before motoric disease onset	47
VCP suppresses proteopathic seeding in neurons	47
Proteomic landscape of Alzheimer’s Disease: novel insights into pathogenesis and biomarker discovery	46
SETD7-mediated monomethylation is enriched on soluble Tau in Alzheimer’s disease	46
Sodium oligomannate alters gut microbiota, reduces cerebral amyloidosis and reactive microglia in a sex-specific manner	44
Sex specific molecular networks and key drivers of Alzheimer’s disease	44
Peripheral and central neuroimmune mechanisms in Alzheimer’s disease pathogenesis	44
NF-κB is a critical mediator of post-mitotic senescence in oligodendrocytes and subsequent white matter loss	44
Mechanisms of astrocyte aging in reactivity and disease	44
Wild-type FUS corrects ALS-like disease induced by cytoplasmic mutant FUS through autoregulation	43
Tracking reactive astrogliosis in autosomal dominant and sporadic Alzheimer’s disease with multi-modal PET and plasma GFAP	41
GBA1 inactivation in oligodendrocytes affects myelination and induces neurodegenerative hallmarks and lipid dyshomeostasis in mice	40
Trem2 deletion enhances tau dispersion and pathology through microglia exosomes	40
Correction: Blood–brain barrier-associated pericytes internalize and clear aggregated amyloid-β42 by LRP1-dependent apolipoprotein E isoform-specific mechanism	40
Amyloid-β (Aβ) immunotherapy induced microhemorrhages are linked to vascular inflammation and cerebrovascular damage in a mouse model of Alzheimer’s disease	38
SRSF1-dependent inhibition of C9ORF72-repeat RNA nuclear export: genome-wide mechanisms for neuroprotection in amyotrophic lateral sclerosis	36
Small molecule inhibitors of α-synuclein oligomers identified by targeting early dopamine-mediated motor impairment in C. elegans	36

Neuropathology and molecular diagnosis of Synucleinopathies	36
Correction: Border-associated macrophages promote cerebral amyloid angiopathy and cognitive impairment through vascular oxidative stress	35
Increased expression of mesencephalic astrocyte-derived neurotrophic factor (MANF) contributes to synapse loss in Alzheimer’s disease	35
Proteomic analysis of APOEε4 carriers implicates lipid metabolism, complement and lymphocyte signaling in cognitive resilience	34
Pathological characteristics of axons and alterations of proteomic and lipidomic profiles in midbrain dopaminergic neurodegeneration induced by WDR45-deficiency	34
Nuclear pore and nucleocytoplasmic transport impairment in oxidative stress-induced neurodegeneration: relevance to molecular mechanisms in Pathogenesis of Parkinson’s and other related neurodegenerat	33
Therapeutic potential of APP antisense oligonucleotides for Alzheimer’s disease and down syndrome-related Alzheimer’s disease	33
Trem2 H157Y increases soluble TREM2 production and reduces amyloid pathology	33
MicroRNA-100-5p and microRNA-298-5p released from apoptotic cortical neurons are endogenous Toll-like receptor 7/8 ligands that contribute to neurodegeneration	32
CCR5 antagonist reduces HIV-induced amyloidogenesis, tau pathology, neurodegeneration, and blood-brain barrier alterations in HIV-infected hu-PBL-NSG mice	32
Mammalian/mechanistic target of rapamycin (mTOR) complexes in neurodegeneration	32
Key role of the CCR2-CCL2 axis in disease modification in a mouse model of tauopathy	32
BACE1 regulates expression of Clusterin in astrocytes for enhancing clearance of β-amyloid peptides	31
The role of inflammasomes in vascular cognitive impairment	31
Blood platelet factor 4: the elixir of brain rejuvenation	31
Proteo-genomics of soluble TREM2 in cerebrospinal fluid provides novel insights and identifies novel modulators for Alzheimer’s disease	31
Correction: Collusion of α-Synuclein and Aβ aggravating co-morbidities in a novel prion-type mouse model	31
Seeding activity of skin misfolded tau as a biomarker for tauopathies	30
Resistant and Resilient mutations in protection against familial Alzheimer’s disease: learning from nature	30
TDP-43 seeding activity in the olfactory mucosa of patients with amyotrophic lateral sclerosis	30
Network proteomics of the Lewy body dementia brain reveals presynaptic signatures distinct from Alzheimer’s disease	30
Age-dependent progression from clearance to vulnerability in the early response of periventricular microglia to α-synuclein toxic species	29
Targeted long-read sequencing to quantify methylation of the C9orf72 repeat expansion	29
Alpha synuclein co-pathology is associated with accelerated amyloid-driven tau accumulation in Alzheimer’s disease	29
Elevated nuclear TDP-43 induces constitutive exon skipping	29
Mitochondrial dysfunction in Parkinson’s disease – a key disease hallmark with therapeutic potential	28
Correction: Trem2 H157Y increases soluble TREM2 production and reduces amyloid pathology	28
HDGFL2 cryptic protein: a portal to detection and diagnosis in neurodegenerative disease	28
Microglial ferroptotic stress causes non-cell autonomous neuronal death	28
Amyloid fibril proteomics of AD brains reveals modifiers of aggregation and toxicity	28
Astrocyte reactivity is associated with tau tangle load and cortical thinning in Alzheimer’s disease	27
Oligodendrocyte death and myelin loss in the cuprizone model: an updated overview of the intrinsic and extrinsic causes of cuprizone demyelination	27
ACSS2-dependent histone acetylation improves cognition in mouse model of Alzheimer’s disease	27
Gut microbiota-host lipid crosstalk in Alzheimer’s disease: implications for disease progression and therapeutics	27
cGAS-STING triggers inflammaging-associated neurodegeneration	27
The integrated stress response in neurodegenerative diseases	26
Loss of MEF2C function by enhancer mutation leads to neuronal mitochondria dysfunction and motor deficits in mice	26
A novel AAV Vector for gene therapy of RPE-related retinal degenerative diseases via intravitreal delivery	26
Astrocytes of the optic nerve exhibit a region-specific and temporally distinct response to elevated intraocular pressure	26
Microglial CD2AP deficiency exerts protection in an Alzheimer’s disease model of amyloidosis	26
An adapted protocol to derive microglia from stem cells and its application in the study of CSF1R-related disorders	26
Mitochondrial CISD1/Cisd accumulation blocks mitophagy and genetic or pharmacological inhibition rescues neurodegenerative phenotypes in Pink1/parkin models	26
Specific detection of tau seeding activity in Alzheimer’s disease using rationally designed biosensor cells	25
TREM2 and microglia exosomes: a potential highway for pathological tau	25
Pharmacological rescue of cognitive function in a mouse model of chemobrain	25
Immune cell metabolic dysfunction in Parkinson’s disease	25
Retinal ganglion cell repopulation for vision restoration in optic neuropathy: a roadmap from the RReSTORe Consortium	24
TDP-43 pathology is associated with increased tau burdens and seeding	24
Current views on meningeal lymphatics and immunity in aging and Alzheimer’s disease	24
Whole-genome sequencing analysis reveals new susceptibility loci and structural variants associated with progressive supranuclear palsy	24
Knock-in models related to Alzheimer’s disease: synaptic transmission, plaques and the role of microglia	23
Nuclear import receptors are recruited by FG-nucleoporins to rescue hallmarks of TDP-43 proteinopathy	23
Transcriptome deregulation of peripheral monocytes and whole blood in GBA-related Parkinson’s disease	23
A Trem2R47H mouse model without cryptic splicing drives age- and disease-dependent tissue damage and synaptic loss in response to plaques	23
Are oligodendrocytes the missing link in Alzheimer’s disease and related dementia research?	23
Aging-associated sensory decline and Alzheimer’s disease	23
“Don’t Phos Over Tau”: recent developments in clinical biomarkers and therapies targeting tau phosphorylation in Alzheimer’s disease and other tauopathies	22
hiPSC-based models to decipher the contribution of human astrocytes to Alzheimer’s disease and potential therapeutics	22
Nuclear-import receptors as gatekeepers of pathological phase transitions in ALS/FTD	22
Edaravone activates the GDNF/RET neurotrophic signaling pathway and protects mRNA-induced motor neurons from iPS cells	22
Correction: Whole-genome sequencing analysis reveals new susceptibility loci and structural variants associated with progressive supranuclear palsy	22
Post-infection cognitive impairments in a cohort of elderly patients with COVID-19	22
Non-invasive systemic viral delivery of human alpha-synuclein mimics selective and progressive neuropathology of Parkinson’s disease in rodent brains	22
TDP-43-regulated cryptic RNAs accumulate in Alzheimer’s disease brains	22
The neuroimmune nexus: unraveling the role of the mtDNA-cGAS-STING signal pathway in Alzheimer’s disease	21
Inactivation of NLRP3 inflammasome by dephosphorylation at Serine 658 alleviates glial inflammation in the mouse model of Parkinson’s disease	21
Fate-mapping and functional dissection reveal perilous influence of type I interferon signaling in mouse brain aging	21
Single-domain antibody-based protein degrader for synucleinopathies	21
Tau protein profiling in tauopathies: a human brain study	20
Lewy body diseases and the gut	20
Does proteopathic tau propagate trans-synaptically in the brain?	20
Functional microRNA targetome undergoes degeneration-induced shift in the retina	20
The concept of resilience to Alzheimer’s Disease: current definitions and cellular and molecular mechanisms	20
When the infectious environment meets the AD brain	19
BIN1 is a key regulator of proinflammatory and neurodegeneration-related activation in microglia	19
Tauopathies: new perspectives and challenges	19
18F-MK-6240 tau PET in patients at-risk for chronic traumatic encephalopathy	19
Translation dysregulation in neurodegenerative diseases: a focus on ALS	19
Alzheimer’s genes in microglia: a risk worth investigating	19
Genome-wide analyses identify NEAT1 as genetic modifier of age at onset of amyotrophic lateral sclerosis	18

Advanced structural brain aging in preclinical autosomal dominant Alzheimer disease	18
A blood-based diagnostic test incorporating plasma Aβ42/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort validity analysis	18
Calcium-dependent cytosolic phospholipase A2 activation is implicated in neuroinflammation and oxidative stress associated with ApoE4	17
CD8+ T cells in neurodegeneration: friend or foe?	17
To the editor: Response to post-infection cognitive impairments in a cohort of elderly patients with COVID-19, by Wang, Y.J. et al. (2021)	17
Genetic context modulates aging and degeneration in the murine retina	17
Disparate and shared transcriptomic signatures associated with cortical atrophy in genetic behavioral variant frontotemporal degeneration	17
Simple model systems reveal conserved mechanisms of Alzheimer’s disease and related tauopathies	17
Crosstalk of organelles in Parkinson’s disease – MiT family transcription factors as central players in signaling pathways connecting mitochondria and lysosomes	16
Comparison of immunoassay- with mass spectrometry-derived p-tau quantification for the detection of Alzheimer’s disease pathology	16
Insights from new in vivo models of TREM2 variants	16
Regulation of human microglial gene expression and function via RNAase-H active antisense oligonucleotides in vivo in Alzheimer’s disease	16
Correction: Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer’s disease	16
The Alzheimer’s disease-linked protease BACE1 modulates neuronal IL-6 signaling through shedding of the receptor gp130	15
Nuclear speckle specific hnRNP D-like prevents age- and AD-related cognitive decline by modulating RNA splicing	15
Urolithin A promotes p62-dependent lysophagy to prevent acute retinal neurodegeneration	15
Alzheimer’s disease associated isoforms of human CD33 distinctively modulate microglial cell responses in 5XFAD mice	15
Variants in the MS4A cluster interact with soluble TREM2 expression on biomarkers of neuropathology	15
Single-cell microglial transcriptomics during demyelination defines a microglial state required for lytic carcass clearance	15
Real-time imaging of mitochondrial redox reveals increased mitochondrial oxidative stress associated with amyloid β aggregates in vivo in a mouse model of Alzheimer’s disease	15
Author response to “post-infection cognitive impairments in a cohort of elderly patients with COVID-19”	14
17q21.31 sub-haplotypes underlying H1-associated risk for Parkinson’s disease are associated with LRRC37A/2 expression in astrocytes	14
The role of inflammation in neurodegeneration: novel insights into the role of the immune system in C9orf72 HRE-mediated ALS/FTD	14
RNA-Targeting CRISPR/CasRx system relieves disease symptoms in Huntington’s disease models	14
TREM2 and sTREM2 in Alzheimer’s disease: from mechanisms to therapies	14
Dynamic changes of CSF sPDGFRβ during ageing and AD progression and associations with CSF ATN biomarkers	14
Updates on mouse models of Alzheimer’s disease	14
Research models to study lewy body dementia	13
Mitovesicles secreted into the extracellular space of brains with mitochondrial dysfunction impair synaptic plasticity	13
Regulatory T cells limit age-associated retinal inflammation and neurodegeneration	13
Altered plasma protein profiles in genetic FTD – a GENFI study	13
Proteostasis failure exacerbates neuronal circuit dysfunction and sleep impairments in Alzheimer’s disease	13
Translational molecular imaging and drug development in Parkinson’s disease	12
METTL3-dependent RNA m6A dysregulation contributes to neurodegeneration in Alzheimer’s disease through aberrant cell cycle events	12
Drug development targeting degeneration of the basal forebrain cholinergic system: its time has come	12
ApoE in Alzheimer’s disease: pathophysiology and therapeutic strategies	11
Extracellular protein components of amyloid plaques and their roles in Alzheimer’s disease pathology	11
A microglial activity state biomarker panel differentiates FTD-granulin and Alzheimer’s disease patients from controls	11
A proteomic network approach resolves stage-specific molecular phenotypes in chronic traumatic encephalopathy	11
Chitinase-3-like-1: a multifaceted player in neuroinflammation and degenerative pathologies with therapeutic implications	10
Clarifying the association of CSF Aβ, tau, BACE1, and neurogranin with AT(N) stages in Alzheimer disease	10
Impaired antioxidant KEAP1-NRF2 system in amyotrophic lateral sclerosis: NRF2 activation as a potential therapeutic strategy	10
TDP-43 Pathology in Alzheimer’s Disease	10
AMPK hyperactivation promotes dendrite retraction, synaptic loss, and neuronal dysfunction in glaucoma	10
Valosin containing protein (VCP): initiator, modifier, and potential drug target for neurodegenerative diseases	10
Common mouse models of tauopathy reflect early but not late human disease	10
Correction: Drug development targeting degeneration of the basal forebrain cholinergic system: its time has come	10
The informed road map to prevention of Alzheimer Disease: A call to arms	10
CSF protein ratios with enhanced potential to reflect Alzheimer’s disease pathology and neurodegeneration	10
Correction: Alzheimer risk gene product Pyk2 suppresses tau phosphorylation and phenotypic effects of tauopathy	10